Lunai Bioworks (LNAI) Common Equity (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Common Equity of -$9.6 million for Q1 2026, down 110.81% year-over-year from $88.4 million in Q1 2025, and up 29.49% quarter-over-quarter from -$13.5 million in Q4 2025.
Lunai Bioworks (LNAI) Common Equity (2011 - 2026) Analysis & Trends
Lunai Bioworks' Common Equity history runs 16 years deep, the most recent figure standing at -$9.6 million for Q1 2026.
- In Q1 2026, Common Equity fell 110.81% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$9.6 million (down 110.81% YoY), while the FY2025 annual figure was -$21.3 million, down 116.18% from the prior year.
- Common Equity for Q1 2026 stood at -$9.6 million, up from -$13.5 million in the prior quarter.
- The five-year high for Common Equity was $161.2 million in Q1 2022, with the low at -$21.3 million in Q2 2025.
- The 5-year median for Common Equity is $66.9 million (2022), against an average of $61.9 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 183.81% in 2024, then slumped 116.51% in 2025.
- Lunai Bioworks' Common Equity stood at $66.9 million in 2022, then plunged by 34.83% to $43.6 million in 2023, then jumped by 88.23% to $82.1 million in 2024, then plunged by 116.51% to -$13.5 million in 2025, then advanced by 29.49% to -$9.6 million in 2026.
- Business Quant data shows LNAI's Common Equity at -$9.6 million in Q1 2026, -$13.5 million in Q4 2025, and -$13.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.79 Bn |
| 10 | Lunai Bioworks | 6.78 Mn | 3.62 Mn | 20,942.00 | -9.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.55 Mn |
| Dec 31, 2025 | -13.55 Mn |
| Sep 30, 2025 | -13.04 Mn |
| Jun 30, 2025 | -21.35 Mn |
| Mar 31, 2025 | 88.39 Mn |
| Dec 31, 2024 | 82.06 Mn |
| Sep 30, 2024 | 98.09 Mn |
| Jun 30, 2024 | 131.98 Mn |
| Mar 31, 2024 | 134.41 Mn |
| Dec 31, 2023 | 43.60 Mn |
| Sep 30, 2023 | 46.75 Mn |
| Jun 30, 2023 | 46.50 Mn |
| Mar 31, 2023 | 66.13 Mn |
| Dec 31, 2022 | 66.90 Mn |
| Sep 30, 2022 | 70.32 Mn |
| Jun 30, 2022 | 72.62 Mn |
| Mar 31, 2022 | 161.24 Mn |
| Dec 31, 2021 | 165.62 Mn |
| Sep 30, 2021 | 166.97 Mn |
| Jun 30, 2021 | 174.66 Mn |